Literature DB >> 17027889

Neuromyelitis optica - Devic's syndrome, update.

Raul N Mandler1.   

Abstract

Neuromyelitis optica of Devic (NMO) is a syndrome which combines transverse myelitis and optic neuritis. For many years it was assumed that transverse myelitis and optic neuritis should be simultaneous, that optic neuritis should be bilateral, and that transverse myelitis must be complete. NMO was considered to be very rare. Through the 20th century there was a debate on whether NMO is a distinct nosologic entity or a form of MS. In 2005 it is now possible to distinguish NMO from MS on the basis of the clinical, imaging, serology and immunopathology profile. This distinction is necessary for the implementation of adequate treatments, as the relapsing form of the illness carries significant morbidity and mortality.

Entities:  

Mesh:

Year:  2006        PMID: 17027889     DOI: 10.1016/j.autrev.2006.02.008

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  17 in total

1.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

2.  IL-21R signaling is critical for induction of spontaneous experimental autoimmune encephalomyelitis.

Authors:  Youjin Lee; Meike Mitsdoerffer; Sheng Xiao; Guangxiang Gu; Raymond A Sobel; Vijay K Kuchroo
Journal:  J Clin Invest       Date:  2015-09-28       Impact factor: 14.808

Review 3.  Novel molecular targets in the treatment of systemic lupus erythematosus.

Authors:  José C Crispín; George C Tsokos
Journal:  Autoimmun Rev       Date:  2007-12-04       Impact factor: 9.754

4.  Aquaporin 4 molecular mimicry and implications for neuromyelitis optica.

Authors:  Radhika A Vaishnav; Ruolan Liu; Joab Chapman; Andrew M Roberts; Hong Ye; Jovan D Rebolledo-Mendez; Takeshi Tabira; Alicia H Fitzpatrick; Anat Achiron; Mark P Running; Robert P Friedland
Journal:  J Neuroimmunol       Date:  2013-05-09       Impact factor: 3.478

5.  Neuromyelitis optica in a young child with positive serum autoantibody.

Authors:  Ingrid P Loma; Miya R Asato; Robyn A Filipink; Gulay Alper
Journal:  Pediatr Neurol       Date:  2008-09       Impact factor: 3.372

6.  Effectiveness of multi-disciplinary rehabilitation for patients with Neuromyelitis Optica.

Authors:  Yael Nechemia; Elior Moreh; Harold Weingarden; Ayala Bloch; Uri Givon; Adi Vaknin-Dembinsky; Isabella Schwartz; Zeev Meiner; Gabi Zeilig
Journal:  J Spinal Cord Med       Date:  2016-03-24       Impact factor: 1.985

7.  Long-term outcome of acute and subacute myelopathies.

Authors:  S Debette; J de Sèze; J-P Pruvo; H Zephir; F Pasquier; D Leys; P Vermersch
Journal:  J Neurol       Date:  2009-02-28       Impact factor: 4.849

8.  New insights into neuromyelitis optica.

Authors:  Woojun Kim; Su-Hyun Kim; Ho Jin Kim
Journal:  J Clin Neurol       Date:  2011-09-29       Impact factor: 3.077

Review 9.  Neuromyelitis optica pathogenesis and aquaporin 4.

Authors:  David J Graber; Michael Levy; Douglas Kerr; William F Wade
Journal:  J Neuroinflammation       Date:  2008-05-29       Impact factor: 8.322

10.  Regional gray matter atrophy and neuropsychologcal problems in relapsing-remitting multiple sclerosis.

Authors:  Aiyu Lin; Fuyong Chen; Fang Liu; Zhiwen Li; Ying Liu; Shifang Lin; Xiaoyi Wang; Jiting Zhu
Journal:  Neural Regen Res       Date:  2013-07-25       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.